MTIP
LGND icon

Magee Thomson Investment Partners’s Ligand Pharmaceuticals LGND Stock Holding History

Magee Thomson Investment Partners’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-5,493
Closed -$183K – 115
2014
Q4 		$183K Hold
5,493
– – 0.05% 63
2014
Q3 		$162K Hold
5,493
– – 0.04% 68
2014
Q2 		$214K Buy
5,493
+969
+21% +$39.3K 0.05% 60
2014
Q1 		$190K Hold
4,524
– – 0.04% 68
2013
Q4 		$149K Buy
4,524
+2,100
+87% +$68.4K 0.03% 85
2013
Q3 		$65K Buy
+2,424
New +$68.2K 0.01% 89

Other funds holding LGND

William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Magee Thomson Investment Partners's LGND Position: Q1 2015 in Review

Magee Thomson Investment Partners sold out of Ligand Pharmaceuticals (LGND) in Q1 2015, closing a stake of 5,493 shares — an estimated $183K sold.

Magee Thomson Investment Partners first reported a position in LGND in Q3 2013 and held it in 6 quarters. The position peaked at $214K in Q2 2014. 187 funds tracked by Wall St. Rank hold LGND as of Q1 2015.

  • Magee Thomson Investment Partners reported no remaining Ligand Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
  • Magee Thomson Investment Partners sold 5,493 Ligand Pharmaceuticals shares in Q1 2015, an estimated $183K.
  • Magee Thomson Investment Partners first reported a position in Ligand Pharmaceuticals in Q3 2013 and held it in 6 quarters.
  • Magee Thomson Investment Partners's Ligand Pharmaceuticals position peaked at $214K in Q2 2014.
  • 187 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2015.

Based on Magee Thomson Investment Partners's 13F filing for Q1 2015, filed 4 May 2015.